MG53: A new protagonist in the precise treatment of cardiomyopathies.
Biochem Pharmacol
; 222: 116057, 2024 04.
Article
de En
| MEDLINE
| ID: mdl-38367817
ABSTRACT
Cardiomyopathies (CMs) are highly heterogeneous progressive heart diseases characterised by structural and functional abnormalities of the heart, whose intricate pathogenesis has resulted in a lack of effective treatment options. Mitsugumin 53 (MG53), also known as Tripartite motif protein 72 (TRIM72), is a tripartite motif family protein from the immuno-proteomic library expressed primarily in the heart and skeletal muscle. Recent studies have identified MG53 as a potential cardioprotective protein that may play a crucial role in CMs. Therefore, the objective of this review is to comprehensively examine the underlying mechanisms mediated by MG53 responsible for myocardial protection, elucidate the potential role of MG53 in various CMs as well as its dominant status in the diagnosis and prognosis of human myocardial injury, and evaluate the potential therapeutic value of recombinant human MG53 (rhMG53) in CMs. It is expected to yield novel perspectives regarding the clinical diagnosis and therapeutic treatment of CMs.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Cardiomyopathies
/
Myocarde
Limites:
Humans
Langue:
En
Journal:
Biochem Pharmacol
/
Biochem. pharmacol
/
Biochemical pharmacology
Année:
2024
Type de document:
Article
Pays de publication:
Royaume-Uni